SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Medico Remedies surges on commencing work for new factory

16 May 2025 Evaluate

Medico Remedies is currently trading at Rs. 54.74, up by 1.52 points or 2.86% from its previous closing of Rs. 53.22 on the BSE.

The scrip opened at Rs. 52.20 and has touched a high and low of Rs. 54.74 and Rs. 52.20 respectively. So far 6018 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 79.78 on 06-Feb-2025 and a 52 week low of Rs. 35.00 on 05-Jun-2024.

Last one week high and low of the scrip stood at Rs. 56.00 and Rs. 50.33 respectively. The current market cap of the company is Rs. 453.26 crore.

The promoters holding in the company stood at 63.79%, while Institutions and Non-Institutions held 0.13% and 36.08% respectively.

Medico Remedies has commenced work for new factory for manufacturing of B lactum tablets, capsules, dry syrup and injections (including amoxycillin and clauvulinic acid formulations). This plant will have capacity of 25 million tablets, 45 million capsules,10 million dry syrups, 10 million injectables. The investment required for this capacity is Rs 30 crore. The proposed capacity is to be added within 2 years.

The state-of-the-art facility in going to be made as per PIC/S guidelines. It is expected to add about 25 crore revenue after receiving all approvals.

Medico Remedies is a leading manufacturer and exporter of pharmaceutical formulations including tablets, capsules and suspensions.

Medico Remedies Share Price

41.24 1.77 (4.48%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×